Qualifications: Associate Degree in related area 4 years of experience in a biotech/pharma manufacturing/laboratory...QUALITY CONSULTING GROUP, a leader in the pharmaceutical, biotech, medical devices, and manufacturing industry...
's Degree required; sales/marketing or science related degree preferred Requires 5-8 years Pharma, Biotech or Medical Device... Role Description Overall Objective: The Therapeutic Sales Specialist represents LEO Pharma Inc. within an assigned...
Qualifications: Associate Degree in related area 4 years of experience in a biotech/pharma manufacturing/laboratory...QUALITY CONSULTING GROUP, a leader in the pharmaceutical, biotech, medical devices, and manufacturing industry...
) to drive the companys strategic and operational goals, secure pharma and biotech partnerships, and work alongside leadership... affairs, statistical programming, and other R&D areas within pharma and biotech. He has more than ten years of recruiting...
650 clients ranging from innovative biotech start-ups to established pharmaceutical companies. Our products, services.... Job Description The EVERSANA/Millicent Pharma Specialty Pharmaceutical Representative will be responsible for selling Intrarosa & Femring...
Indian state-owned companies' stocks surged in FY24, outperforming mid- and small-cap stocks. BSE PSU index nearly doubled, boosted by govt's capex spending hike and anticipated BJP victory. Railway, power, defence, and oil sectors also showed impressive gains. Continue Reading »
Ecos Mobility and Hospitality IPO consists of an offer for sale (OFS) of a maximum of 18,000,000 equity shares, comprising of up to 9,900,000 equity shares by Rajesh Loomba and up to 8,100,000 equity shares by Aditya Loomba. Continue Reading »
MCX gold price rallied more than 12% in FY24, the fiscal year that saw a slew of global conflicts including the Israel - Hamas war and the ongoing Russia - Ukraine war. Continue Reading »
Over the past five years, the earnings per share of I-Sec has doubled but the price-to-earnings multiple indicates a drop in valuation amid intense competition in the brokerage business Continue Reading »
Expert View : Kunal Vora, Head of India Equity Research, BNP Paribas said that Domestic flows have become the bedrock of Indian Equities. However, valuations are looking expensive for the market as a whole and most of the key sectors. December 2025 Nifty-50 target of 23,500, implies a 6-7% return Continue Reading »